February 16, 2024: NCHR provides written testimony to the Maryland House of Delegates Environment and Transportation Committee to support HB457, which requires transparency regarding all new artificial turf and infill installation, use, reuse, recycling, and disposal. This information would enable communities to make informed decisions about artificial turf that take into account how long it lasts and its impact on the environment.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR Agrees with CDC Draft Recommendation to Remove Liraglutide and Pertuzumab from the National Institute for Occupational Safety and Health Hazardous Drugs in Healthcare Settings List
February 15th, 2024: NCHR supports the CDC recommendation to remove Liraglutide and Pertuzumab drugs from the NIOSH List of Hazardous Drugs in Healthcare Settings. We agree that due to the to the drugs’ low bioavailability and limited risk of occupational exposures these drugs are unlikely to pose a harm to healthcare workers.
Read More »Comments of National Center for Health Research on USPSTF Draft Research Plan for BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing
February 14, 2024: NCHR supports USPSTF BRCA-Related Cancer research plan but recommends evaluating the impact of how risk information is explained in genetic counseling & treatment options. Our primary concern is providing short-term and long-term risk information and absolute risk and benefit statistics as well as relative risks and benefits.
Read More »NCHR Comment- Menu Labeling: Supplemental Guidance for Industry (Edition 2)
The FDA recommends that chain restaurants publish information on calories and added sugars on standard menus and also on third-party platforms such as Grubhub and Ubereats. NCHR agrees with FDA’s plan to improve info available to consumers but urges the agency to make these recommendations mandatory to ensure the compliance needed to provide useful health information to consumers.
Read More »Medicare has different standards than the FDA. That’s how it should be
STAT News, February 2, 2024: NCHR’s Diana Zuckerman’s commentary in STAT News explains why Medicare should not pay for every medical product that FDA approves, since some are more likely to harm rather than help Medicare patients. She points out that FDA does not require diversity in clinical trials and rarely includes enough older and less healthy patients that tend to rely on Medicare.
Read More »